BioNTech and partner Pfizer warned on Monday that they had no evidence that their jointly developed vaccine will continue to protect against COVID-19 if the booster shot is given later than tested in trials.
Visit our dedicated coronavirus site here for all the latest updates.
“The safety and efficacy of the vaccine has not been evaluated on different dosing schedules as the majority of trial participants received the second dose within the window specified in the study design,” the companies said in a joint statement, referring to prime and a booster shots given three weeks apart.
Read more:
Coronavirus: EU drugs agency still undecided on Moderna COVID-19 vaccine
Coronavirus: UK prime minister orders new national lockdown
Coronavirus: New York, Florida tell hospitals to dispense COVID-19 vaccines quicker
